119 related articles for article (PubMed ID: 25911348)
1. Ovary removal is linked to lower breast cancer mortality in BRCA1 carriers.
Wise J
BMJ; 2015 Apr; 350():h2182. PubMed ID: 25911348
[No Abstract] [Full Text] [Related]
2. Association of risk-reducing surgery with cancer risks and mortality in BRCA mutation carriers.
Heemskerk-Gerritsen BA; Kriege M; Seynaeve C
JAMA; 2010 Dec; 304(24):2695; author reply 2695-6. PubMed ID: 21177502
[No Abstract] [Full Text] [Related]
3. Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?
Brekelmans CT; Seynaeve C
Lancet Oncol; 2006 Mar; 7(3):191-3. PubMed ID: 16510328
[No Abstract] [Full Text] [Related]
4. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
[TBL] [Abstract][Full Text] [Related]
5. Strategies for ovarian cancer prevention.
Dann RB; Kelley JL; Zorn KK
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
[TBL] [Abstract][Full Text] [Related]
6. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
[TBL] [Abstract][Full Text] [Related]
7. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
Biglia N; Mariani L; Ponzone R; Sismondi P
Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
[No Abstract] [Full Text] [Related]
8. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
9. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
Agnantis NJ; Paraskevaidis E; Roukos D
Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
[No Abstract] [Full Text] [Related]
10. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
Roukos DH; Agnanti NJ; Paraskevaidis E; Kappas AM
Ann Surg Oncol; 2002 Dec; 9(10):941-3. PubMed ID: 12464584
[No Abstract] [Full Text] [Related]
11. Prophylactic surgery recommended for BRCA1 carriers.
Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
[No Abstract] [Full Text] [Related]
12. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
Domchek SM; Rebbeck TR
LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
[TBL] [Abstract][Full Text] [Related]
13. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
[No Abstract] [Full Text] [Related]
14. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
Olivier RI; van Beurden M
Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
[No Abstract] [Full Text] [Related]
15. Hereditary breast and ovarian cancer syndrome.
ACOG Committee on Practice Bulletins
Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
[No Abstract] [Full Text] [Related]
16. Choices--and uncertainties--for women with BRCA mutations.
Couzin J
Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
[No Abstract] [Full Text] [Related]
17. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
Rebbeck TR
J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
[TBL] [Abstract][Full Text] [Related]
18. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
19. Improving surveillance and quality of life of BRCA mutation carriers.
Loman N; Borg A
J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
[No Abstract] [Full Text] [Related]
20. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
